
Gilead Sciences Expands Autoimmune Pipeline with Acquisition of Ouro Medicines
Gilead Sciences Moves to Acquire Ouro Medicines, Strengthening Its Autoimmune and Inflammation Pipeline with Innovative T-Cell Engager Technology Gilead Sciences has announced a major strategic step to expand its presence in the autoimmune disease space through a definitive agreement to…












